Does endometrial integrin expression in endometriosis patients predict enhanced in vitro fertilization cycle outcomes after prolonged GnRH agonist therapy?

Eric S. Surrey, Surrey ES, Lietz AK, A K Lietz, Annette K Lietz, R.L. Gustofson, Gustofson RL, Robert L Gustofson, Minjarez DA, Debra A. Minjarez, Schoolcraft WB, William B. Schoolcraft
Fertility and sterility · 2009 · vol. 93(2) , pp. 646–651 · doi:10.1016/j.fertnstert.2008.12.023 · PMID:19171333 · W2028603234
article OA: closed CC0 ⤵ 12 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

This study investigated whether endometrial integrin expression in women with endometriosis predicts improved IVF outcomes following extended GnRH agonist treatment.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

ObjectiveTo determine whether endometrial expression of the integrin alpha(v)beta(3) vitronectin can predict which endometriosis patient subgroup will benefit from pre-IVF cycle prolonged GnRH agonist (GnRHa) therapy.DesignProspective randomized institutional review board approved pilot trial.SettingPrivate assisted reproductive technology program.Patient(s)IVF candidates with regular menses, surgically confirmed endometriosis, and normal ovarian reserve.Intervention(s)All patients underwent endometrial biopsy 9 to 11 days post-LH surge to evaluate alpha(v)beta(3) integrin expression. Patients were randomized either to receive depot leuprolide acetate 3.75 mg every 28 days for three doses before controlled ovarian hyperstimulation (COH) or to proceed directly to COH and IVF. Group 1: integrin-positive controls (N = 12); group 2: integrin-positive administered prolonged GnRHa (N = 8). Group A: integrin-negative controls (N = 7); group B: integrin-negative administered prolonged GnRHa (N = 9).Main outcome measure(s)COH responses, ongoing pregnancy and implantation rates.ResultsThere were no significant effects of GnRH agonist treatment in either of the integrin expression strata regarding ongoing pregnancy or implantation rates, although these outcomes were more frequent in group 2 vs. 1 (62.5% vs. 41.6% and 35% vs. 20.6%, respectively). This effect may have because of limited sample size. The value of a negative integrin biopsy in predicting an ongoing pregnancy after prolonged GnRH agonist therapy was only 44.4%.Conclusion(s)Endometrial alpha(v)beta(3) integrin expression did not predict which endometriosis patients would benefit from prolonged GnRHa therapy before IVF.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Embryo Implantation Endometriosis Endometriosis Fertilization in Vitro Gonadotropin-Releasing Hormone Integrin alphaVbeta3 Adult Embryo Implantation Endometriosis Endometriosis Female Fertilization in Vitro Gonadotropin-Releasing Hormone Humans Integrin alphaVbeta3 Oocyte Retrieval Oocyte Retrieval Ovarian Hyperstimulation Syndrome Ovarian Hyperstimulation Syndrome Ovary

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (30)

Cited by (12)

Source provenance

europepmc
last seen: 2026-08-15T06:15:18.721777+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:14:18.065553+00:00
License: CC0 · commercial use OK